|
Summary: In May 2026, the Endocrine Society and more than 50 patient and professional organizations announced that Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The renaming was led by an international panel and published in The Lancet. The change reflects what research has confirmed: the condition is not actually about ovarian cysts. It is a complex hormonal and metabolic condition. A three-year transition is underway, with full implementation in the 2028 International Guideline update. This article explains what changed, why, and what the new name means. |
PCOS Has a New Name
In May 2026, after fourteen years of global collaboration, the condition long known as Polycystic Ovary Syndrome was officially renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The Endocrine Society describes the effort as the largest initiative ever undertaken to change the name of a medical condition.
According to the Endocrine Society announcement, PMOS affects approximately 1 in 8 women globally, or more than 170 million women worldwide. The renaming was led by Professor Helena Teede of Monash University in collaboration with the International Androgen Excess and PCOS Society, and incorporated input from 56 patient and professional organizations and more than 22,000 patient survey responses. The three-year transition period is now underway, with full implementation scheduled for the 2028 International Guideline update.
Why the Name Changed
The short version: “polycystic” was never accurate, and “ovary syndrome” was never the whole picture.
In the announcement, Professor Teede stated, “What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated.” According to the Endocrine Society, a related paper published alongside the renaming confirmed no increase in abnormal ovarian cysts in women with the condition.
The old name focused attention on the ovaries, but the condition involves multiple hormonal systems, metabolic features, and effects on weight, mental health, skin, and the reproductive system. The narrow framing contributed to missed diagnoses and inadequate care over decades.
What “Polyendocrine Metabolic Ovarian Syndrome” Actually Means
Each word in the new name was chosen deliberately. Breaking it down clarifies what the condition is:
Polyendocrine
“Poly” means many. “Endocrine” refers to the body’s hormone-producing glands and the signaling system between them. PMOS involves multiple hormonal systems at once, not just reproductive hormones.
Metabolic
The metabolic dimension is now recognized as central to PMOS, not a side effect. Including “metabolic” in the name signals that this is part of the diagnosis and management conversation, not an afterthought.
Ovarian
The ovaries are still involved. The renaming does not remove ovarian considerations. It places them alongside the other systems rather than at the center.
Syndrome
PMOS, like PCOS before it, is a syndrome. That means it is defined by a cluster of features rather than a single test result, and presentation varies from woman to woman.
How PMOS Shows Up
PMOS presents differently from one woman to the next. According to the Endocrine Society, the condition is characterized by fluctuations in hormones with impacts on weight, metabolic and mental health, skin, and the reproductive system. Persistent symptoms in any of these areas warrant evaluation by a qualified healthcare provider, who can diagnose PMOS and recommend an appropriate care plan.
What the Three-Year Transition Means
The new name was announced in May 2026. Full implementation is scheduled for the 2028 International Guideline update. During the transition, both PMOS and PCOS will appear in clinical settings, research, and educational resources. If you have an existing diagnosis or care plan, your healthcare provider will guide you on terminology. The condition itself is the same. Only the name is changing.
Quick Reference: PMOS and the Rename
|
What is PMOS? PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is the new name, announced in May 2026, for the condition previously known as Polycystic Ovary Syndrome (PCOS). According to the Endocrine Society, it affects approximately 1 in 8 women globally and is characterized by hormonal fluctuations with impacts on weight, metabolic and mental health, skin, and the reproductive system. |
|
Why was PCOS renamed? Research confirmed that the “cysts” in PCOS are not actually cysts, and the condition is not primarily about ovaries. The Endocrine Society reported that the old name reduced a complex hormonal and metabolic condition to a misleading focus on ovarian morphology, which contributed to missed diagnoses and inadequate care. |
|
When does the name change take effect? The new name was announced in May 2026. A three-year transition period is in place, with full implementation in the 2028 International Guideline update. During the transition, both PMOS and PCOS will be used. |
Frequently Asked Questions
Is PCOS still called PCOS?
During the three-year transition period that began in May 2026, both names are in use. The official new name is Polyendocrine Metabolic Ovarian Syndrome (PMOS), with full implementation scheduled for the 2028 International Guideline update.
What does PMOS stand for?
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. “Polyendocrine” reflects the multiple hormone systems involved. “Metabolic” recognizes the metabolic features of the condition. “Ovarian” acknowledges that the ovaries are involved without making them the sole focus. “Syndrome” indicates that the condition is defined by a cluster of features.
Who decided to rename PCOS?
According to the Endocrine Society, the name change was led by Professor Helena Teede of Monash University and Professor Terhi Piltonen of Oulu University, in collaboration with the International Androgen Excess and PCOS Society, the Endocrine Society, and more than 50 patient and professional organizations worldwide. The full announcement was published in The Lancet in May 2026.
How many women are affected by PMOS?
The Endocrine Society reports that PMOS affects approximately 1 in 8 women globally, or more than 170 million women worldwide.
About Lemme Balance
Lemme Balance is a daily women’s hormone health supplement featuring the clinically researched 40:1 ratio of Myo-Inositol to D-Chiro Inositol (2,000mg / 50mg), along with Chromium Picolinate (200mcg), Methylated Folate (340mcg), Vitamin D3 (400 IU), and Spearmint Leaf Extract. It is formulated for women interested in supporting hormonal balance, menstrual health, metabolic health, and cycle regularity. Learn more at the Lemme Balance product page.
Lemme Balance is a dietary supplement. It is not a drug, not a treatment, and is not intended to diagnose, treat, cure, or prevent PMOS, PCOS, or any other medical condition. Women with PMOS or suspected PMOS should work with a qualified healthcare provider on their care plan.
Important Information
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and management of PMOS or any other medical condition, and before starting any new supplement regimen.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
-
Endocrine Society. “Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide.” May 12, 2026.
-
Teede HJ, et al. “Renaming polycystic ovary syndrome: a global consensus process.” The Lancet. 2026.
-
Monash Centre for Health Research and Implementation. “PMOS Resources and International Guidelines.” Accessed May 2026.
About the Expert Reviewer
Kathleen Valenton, MD is a board-certified OB/GYN at Rodeo Drive Women’s Health Center in Beverly Hills, CA, with over a decade of experience in women’s health. She completed her internship and residency at Cedars-Sinai Medical Center, where she remains an attending physician, after earning her Medical Degree from the University of Vermont College of Medicine and dual Bachelor’s and Master’s degrees in Psychology from UC Berkeley. Dr. Valenton is also the Chief Medical Officer at Lemme. Her clinical research interests span mental health, hormonal health, infertility, PCOS, and menopause. Dr. Valenton is known for her expertise in pelvic pain, infertility evaluations, and minimally invasive surgery, and remains actively involved in resident education and physician-nursing collaboratives at Cedars-Sinai.
